MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on February 26, 2007; DOI: 10.1124/mol.106.032318


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.032318v1
71/5/1298    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Inaba, Y.
Right arrow Articles by Makishima, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Inaba, Y.
Right arrow Articles by Makishima, M.


Received for publication November 1, 2006.
Revised February 1, 2007.
Accepted for publication February 21, 2007.

Vitamin D3 Derivatives with Adamantane or Lactone Ring Side Chains are Cell Type-Selective Vitamin D Receptor Modulators

Yuka Inaba 1, Keiko Yamamoto 1, Nobuko Yoshimoto 1, Manabu Matsunawa 2, Shigeyuki Uno 2, Sachiko Yamada 2, Makoto Makishima 2*

1 Tokyo Medical and Dental University 2 Nihon University School of Medicine

* Address correspondence to: E-mail: maxima{at}med.nihon-u.ac.jp

Abstract

The vitamin D receptor (VDR) mediates the biological actions of the active form of vitamin D, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], which regulates calcium homeostasis, immunity, cellular differentiation, and other physiological processes. We investigated the effects of three 1,25(OH)2D3 derivatives on VDR function. AD47 has an adamantane ring and LAC67a and LAC67b have lactone ring substituents at the side chain position. These vitamin D derivatives bind to VDR but do not stabilize an active cofactor conformation. In a VDR transfection assay, AD47 and LAC67b act as partial agonists and all three compounds inhibit VDR activation by 1,25(OH)2D3. The derivatives enhanced the heterodimerization of VDR with the retinoid X receptor, an effect unrelated to agonist/antagonist activity. AD47 and LAC67b weakly induced recruitment of the SRC-1 cofactor to VDR, and all three derivatives inhibited the recruitment of p160 family cofactors to VDR induced by 1,25(OH)2D3. Interestingly, AD47 induced DRIP205 recruitment as effectively as 1,25(OH)2D3, while LAC67a and LAC67b were not effective. We examined the expression of endogenous VDR target genes and the nuclear protein levels of VDR and cofactors in several cell lines, including cells derived from intestine, bone and monocytes, and found that the vitamin D3 derivatives act as cell type-selective VDR modulators. The data indicate that side chain modification is useful in the development of VDR antagonists and tissue-selective modulators. Further elucidation of the molecular mechanisms of action of selective VDR modulators will be essential for their clinical application.


Key words: Vitamin D, Transcriptional coactivators, Structure-activity relationships and modeling, Regulation of gene expression


This article has been cited by other articles:


Home page
J. Lipid Res.Home page
M. Ishizawa, M. Matsunawa, R. Adachi, S. Uno, K. Ikeda, H. Masuno, M. Shimizu, K.-i. Iwasaki, S. Yamada, and M. Makishima
Lithocholic acid derivatives act as selective vitamin D receptor modulators without inducing hypercalcemia
J. Lipid Res., April 1, 2008; 49(4): 763 - 772.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics